Extracorporeal hepatocyte-based therapy - Vital Therapies

Drug Profile

Extracorporeal hepatocyte-based therapy - Vital Therapies

Alternative Names: ELAD; Extracorporeal bio-artificial liver; VTL C3A

Latest Information Update: 24 May 2016

Price : $50

At a glance

  • Originator Vital Therapies
  • Class Cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alcoholic hepatitis; Liver failure

Most Recent Events

  • 23 May 2016 Vital Therapies initiates enrolment of patients in the VTI-308 trial for Alcoholic hepatitis and Liver failure (9196496; NCT02612428)
  • 08 Feb 2016 Phase-III clinical trials in Alcoholic hepatitis in Ireland (Extracorporeal) (EudraCT2015-004529-14)
  • 08 Feb 2016 Vital Therapies initiates the phase III VTL-308 trial for Alcoholic hepatitis and Liver failure in Spain (EudraCT2015-004529-14)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top